Cargando…
Inhaled aprotinin reduces viral load in mild‐to‐moderate inpatients with SARS‐CoV‐2 infection
Ejemplares similares
-
Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19
por: Redondo‐Calvo, Francisco Javier, et al.
Publicado: (2022) -
In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment of Candida Albicans Biofilms
por: Heredero-Bermejo, Irene, et al.
Publicado: (2020) -
The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancer
por: Bodoque-Villar, Raquel, et al.
Publicado: (2023) -
A regional Report Card on physical activity in children and adolescents: The case of Extremadura (Spain) in the Global Matrix 4.0
por: Mendoza-Muñoz, María, et al.
Publicado: (2024) -
Ultrastructural Study of Acanthamoeba polyphaga Trophozoites and Cysts Treated In Vitro with Cationic Carbosilane Dendrimers
por: Heredero-Bermejo, Irene, et al.
Publicado: (2020)